503 Clinical activity of ICT01, an anti-BTN3A-targeted, γ9δ2-activating mAb, alone and in combination with pembrolizumab in patients with advanced/refractory solid tumors: EVICTION trial
Wermke M, Marabelle A, Jungels C, Bono J, Vey N, Vicier C, Garralda E, Gouill S, LoRusso P, Champiat S, List C, Aguiar V, Wetzko K, Rhunke L, Gassart A, Brune P, Valentin E, Iche M, Olive D, Frohna P. 503 Clinical activity of ICT01, an anti-BTN3A-targeted, γ9δ2-activating mAb, alone and in combination with pembrolizumab in patients with advanced/refractory solid tumors: EVICTION trial. 2021, a535-a535. DOI: 10.1136/jitc-2021-sitc2021.503.Peer-Reviewed Original ResearchΓ9δ2 T cellsCD8 T cellsRefractory solid tumorsSolid tumor patientsT cellsSolid tumorsTumor patientsBroad antitumor immune responseHospital Universitari Vall d’HebronEthics CommitteeT-cell countsAntitumor immune responseTumor-infiltrating lymphocytesNK cell activationPreliminary efficacy dataInstitut Jules BordetDose-dependent increaseSubsequent clinical benefitCytokine level analysisCommon AEsDose cohortsEudraCT numberLow TILsPhase 1/2aSerum cytokines958O Coordinated activation of antitumor responses of g9d2 and CD8 T-cells by targeting BTN3A with ICT01 in patients with solid tumors: EVICTION trial
Marabelle A, Wermke M, Jungels C, de Bono J, Vey N, Garralda E, Lorusso P, Olive D, Frohna P. 958O Coordinated activation of antitumor responses of g9d2 and CD8 T-cells by targeting BTN3A with ICT01 in patients with solid tumors: EVICTION trial. Annals Of Oncology 2021, 32: s829-s830. DOI: 10.1016/j.annonc.2021.08.1343.Peer-Reviewed Original Research